If you or someone you know is in a medical emergency, call 911. The 988 Suicide and Crisis Lifeline is available 24/7 by call or text.
7-hydroxymitragynine is less than two percent of the alkaloid content in a kratom leaf. Concentrated 7-OH products deliver that same compound isolated, in a form the DEA compares to schedule II opioids like morphine. Withdrawal from it is reported as starting sooner and running harder than kratom leaf withdrawal, though neither has a timeline established in peer-reviewed research.
Kratom leaf and concentrated 7-OH are not the same exposure
Kratom leaf carries mitragynine as its major alkaloid, and 7-hydroxymitragynine is under two percent of it. Products sold as 7-OH deliver that compound isolated, in a form the DEA compares to schedule II opioids such as morphine. Withdrawal from the concentrate is reported as starting sooner and running harder. Read the leaf section for plant material, the 7-OH section for a concentrate.
Key things to know
Four points that decide how to read everything below.
- Neither substance has a published withdrawal timeline. The hour by hour charts on most pages about this topic are not sourced to NIDA, the FDA, the DEA, or any peer reviewed study.
- The difference is dose form, not a different drug. The DEA records 7-hydroxymitragynine as less than two percent of the total alkaloid content of the natural plant, while concentrated products deliver it isolated.
- Leaf withdrawal is better documented. A survey of 293 regular users in Malaysia described the leaf symptom picture in 2014. Concentrated 7-OH withdrawal appears so far in case reports only.
Kratom leaf and concentrated 7-OH withdrawal side by side
The two columns describe stopping two different products, not two different plants. What changes is how much 7-hydroxymitragynine the body has been receiving, and how it arrived.
| Question | Kratom leaf | Concentrated 7-OH |
|---|---|---|
| What the person was taking | Leaf material as powder, capsules, or tea, where mitragynine is the major alkaloid | An isolated or synthesized compound in tablets, shots, or pouches |
| Share of the plant's alkaloids | 7-OH is under two percent of total alkaloid content, or present only in trace amount | Concentrated well past anything the leaf delivers |
| Opioid activity | Mitragynine and 7-OH both act at mu opioid receptors | Profile the DEA compares to schedule II opioids such as morphine |
| Strength of the evidence | A 293 person community survey, Malaysia, 2014 | A nine patient case series and a single case report, both 2026 |
| Reported physical symptoms | Muscle spasms and pain, sleeping difficulty, watery eyes and nose, hot flashes, fever, reduced appetite, diarrhoea | Nausea, diarrhoea, abdominal cramping, restlessness, chills and clamminess |
| Reported psychological symptoms | Restlessness, tension, anger, sadness, nervousness | Anxiety, recorded alongside the physical symptoms in the same case |
| Published timeline | None established | None established |
What kratom leaf withdrawal is
Kratom is the common name for Mitragyna speciosa and for products made from its leaves. The National Institute on Drug Abuse records mitragynine and 7-hydroxymitragynine as its two best studied compounds, and notes that no kratom product is FDA approved for any medical use. People report using it for pain, fatigue, mental health difficulties, and to manage opioid withdrawal.
What the leaf actually contains
The leaf is mitragynine dominant. 7-hydroxymitragynine is a minor alkaloid in it, and the body also makes 7-OH as a metabolite of mitragynine. Potency, alkaloid share, and legal status are covered in this journal's piece on how 7-OH and kratom leaf differ as substances.
Symptoms reported in regular leaf users
The clearest description comes from Singh and colleagues, who surveyed 293 regular kratom users in peninsular Malaysia and published in Drug and Alcohol Dependence in 2014. The physical symptoms reported most often were muscle spasms and pain, difficulty sleeping, watery eyes and nose, hot flashes, fever, reduced appetite, and diarrhoea. Mood suffered too. Restlessness, tension, anger, sadness, and nervousness were the psychological symptoms reported.
More than half of those who had used for longer than six months had developed severe dependence, and 45 percent moderate. This is a 2014 Malaysian community sample using traditional leaf preparations, so it describes that population rather than an American man buying a concentrate at a counter.
What concentrated 7-OH withdrawal is
Products sold as 7-OH are a different proposition. In its notice of intent to temporarily place 7-hydroxymitragynine above a specified threshold in Schedule I, published in the Federal Register on 6 July 2026 under Docket DEA-1570, the DEA records that in natural botanical form 7-OH "makes up less than two percent of the total alkaloid content or occurs in trace amount", and that it can be synthesized from mitragynine in a one step chemical reaction.
How concentrated products differ from the leaf
That same notice states 7-hydroxymitragynine "has opioidergic activity, sharing a similar pharmacological profile to schedule II opioids like morphine", with preclinical data indicating tolerance, dependence, and respiratory depression "comparable to those of classic opioid analgesics". Fenske and colleagues, in the Journal of Addiction Medicine in 2026, add that purified 7-OH may bypass metabolic pathways and deliver disproportionately strong opioid effects compared with natural kratom preparations. The question of why dependence forms so quickly on these products is its own subject.
Symptoms reported in concentrated 7-OH cases
The published picture is thin. Lybik and colleagues reported a single case in the Journal of the American Pharmacists Association in 2026: a 43 year old man who had moved from kratom to concentrated 7-OH roughly 18 months earlier, taking 360 milligrams a day. Around 48 hours after his last dose he presented with nausea, diarrhoea, abdominal cramping, restlessness, chills and clamminess, and anxiety, with a clinical opioid withdrawal scale score of 5. He had switched because the concentrate gave stronger and faster effects at smaller quantities.
Fenske and colleagues reviewed nine patients using purified 7-OH at one telehealth clinic between April and October 2025, with buprenorphine stabilisation succeeding in 88.9 percent. That is one small series at one clinic. Medication decisions belong to a treating physician, and Guiding Road's program is abstinence based.
Why the two withdrawals differ
The same receptor system is involved either way. What changes is how much of the more potent compound reaches it, and how fast.
Dose form and potency
A leaf preparation delivers a mixture in which 7-OH is a minor component, some of it produced afterwards by the body. A concentrate delivers it directly, at a level the plant never reaches. A body adapted to the second is adapting to a stronger opioid signal, and the adjustment when it stops is harder.
Why how long does it last has no published answer
Search this question and you will find confident charts: onset at six to twelve hours, a peak on days two to four, resolution inside a week. Those figures do not appear in the NIDA material, the FDA assessment, the DEA notice, or the peer reviewed literature. They circulate between treatment provider websites quoting one another.
What can be said honestly is narrower. The single published 7-OH case had a man symptomatic around 48 hours after his last dose. The leaf survey described which symptoms appear, not when. Anyone stating exactly how many days this takes is going beyond the evidence.
What is the same about both
The differences are real and they can be overstated. Nothing above makes kratom leaf a safe product to stop unsupervised.
Both are opioid type withdrawal acting on the same receptors. Both produce gastrointestinal symptoms, disturbed sleep, and a psychological component that outlasts the physical one. Both involve dependence that builds quietly, because the dose that prevents withdrawal becomes the reason to keep taking it. In the Malaysian survey, severe dependence was the majority finding after six months of use, and that was leaf.
Risks and when withdrawal is dangerous
Opioid type withdrawal is rarely fatal on its own. The danger comes from what travels with it. Fluid loss, cardiovascular strain, mental health, and whatever else is in the person's system.
Signs that need medical attention
Any one of the following is a reason to involve a clinician rather than continue at home.
- Vomiting or diarrhoea that has caused dehydration, or an inability to keep fluids down.
- Alcohol or benzodiazepines are also being used. Withdrawal from either can involve seizures and needs medical supervision in its own right.
- Other opioids are involved, whether knowingly or through an unlabelled product.
- An existing heart, lung, liver, or kidney condition, or a pregnancy.
- Thoughts of self harm, or a mental health condition that worsens on stopping.
- A previous attempt that involved a seizure, fainting, or an emergency department visit.
Why stopping abruptly on your own is not the safe option
The pattern people describe is repetition. An attempt begins, the symptoms arrive, and the fastest way to end them is the product that caused them. Several attempts ending the same way is information about the withdrawal, not about the person's character.
When withdrawal needs more than waiting it out
Withdrawal is the visible part. Dependence is underneath it, and clearing the compound does not address why he was taking it.
Guiding Road Recovery Center is a men only addiction and mental health program in the Phoenix metro, offering residential treatment, partial hospitalization, intensive outpatient, supportive housing, and treatment for co-occurring mental health conditions. It is accredited by the Joint Commission for behavioral health care. Direct care staffing runs at one staff member to every three clients, and clinicians carry a caseload of six.
Guiding Road does not provide detox on site. Where withdrawal needs clinical supervision first, that is detox coordinated with medical partners, with a place held in the program for when he is medically stable. For someone whose use has settled into concentrated products, 7-OH addiction treatment is the specific pathway.
Recovery is possible and the work is real. What it looks like depends on the person.
Common questions about kratom and 7-OH withdrawal
Is 7-OH withdrawal worse than kratom withdrawal?
It is reported as starting sooner and running harder, but no study has compared the two directly. The reasoning is mechanical: concentrated products deliver a compound the DEA compares to schedule II opioids such as morphine, at levels the leaf never reaches.
How long does kratom withdrawal last?
There is no timeline established in peer reviewed research. The 2014 survey of 293 regular users in Malaysia described which symptoms appear, not how long they run. The figures circulating online are not sourced to NIDA, the FDA, the DEA, or any published study.
How long does concentrated 7-OH withdrawal last?
Also unestablished. The one published case report describes a man symptomatic around 48 hours after his last dose of 360 milligrams a day. A single case cannot be generalised into a timeline, and no larger study has produced one.
What are the symptoms of kratom leaf withdrawal?
In the 2014 survey of 293 regular users, the physical symptoms reported most often were muscle spasms and pain, difficulty sleeping, watery eyes and nose, hot flashes, fever, reduced appetite, and diarrhoea. Restlessness, tension, anger, sadness, and nervousness were the psychological symptoms most often reported.
What are the symptoms of concentrated 7-OH withdrawal?
The published case describes nausea, diarrhoea, abdominal cramping, restlessness, chills and clamminess, and anxiety, presenting around 48 hours after the last dose. That is one patient, so it indicates what can occur rather than what always does.
Is 7-OH the same thing as kratom?
Not in the form sold as 7-OH. 7-hydroxymitragynine occurs in the plant at less than two percent of total alkaloid content, or in trace amount, and the body also produces it as a metabolite of mitragynine. Products marketed as 7-OH are concentrated or synthesized.
Is 7-OH illegal?
Not as of this writing. The DEA published a notice of intent on 6 July 2026 to temporarily place 7-hydroxymitragynine above a specified threshold into Schedule I, and extended the comment period on 26 August 2026. The order had not been issued. State law varies.
Can you withdraw from either one at home?
Some people do. It becomes a medical question rather than a matter of willpower when alcohol, benzodiazepines, or other opioids are also involved, when vomiting or diarrhoea has caused dehydration, when there is a heart, lung, liver, kidney, or pregnancy consideration, or when there are thoughts of self harm.
Does switching from concentrated 7-OH back to kratom leaf help?
No published evidence supports it as a taper strategy, and the direction people describe runs the other way. In the published case, the man moved from kratom to the concentrate because it produced stronger and faster effects at smaller quantities.
Does Guiding Road provide detox?
No. Guiding Road does not provide detox on site. Detox is coordinated as specialty care with medical partners, and a place is held in the men's program for when he is medically stable, so there is no gap between the two steps.
Sources and references
- Drug Enforcement Administration. (2026). Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Docket No. DEA-1570. Federal Register, July 6, 2026. federalregister.gov
- Drug Enforcement Administration. (2026). Hydroxymitragynine Above a Specified Threshold in Schedule I; Extension of Comment Period. Federal Register, August 26, 2026. federalregister.gov
- National Institute on Drug Abuse. Kratom. nida.nih.gov
- Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 139, 132 to 137. doi.org
- Fenske, E., Williams, B., Hallock-Koppelman, L., & Buchheit, B. M. (2026). Buprenorphine for the Management of 7-Hydroxymitragynine (7-OH) Use: A Retrospective Case Series. Journal of Addiction Medicine. pubmed.ncbi.nlm.nih.gov
- Lybik, N., Cone, B., Skelton, S., & Elfessi, Z. (2026). Management of acute withdrawal from 7-hydroxymitragynine after high-dose chronic use: A case report. Journal of the American Pharmacists Association, 66(3). pubmed.ncbi.nlm.nih.gov
- Substance Abuse and Mental Health Services Administration. National Helpline, 1-800-662-4357. samhsa.gov
Get Help at Guiding Road
If he is trying to stop kratom or a concentrated 7-OH product and keeps ending up back where he started, that is a withdrawal problem with a clinical answer. Guiding Road is a men only program in the Phoenix metro, and the admissions team can talk through what level of care fits and coordinate a medical detox bed with a partner facility where that is the first step.
Clinically reviewed by
Bobby Boykin, MS, LASAC, CRS
Executive Director, Guiding Road Recovery Center
Clinical content on this page, including the receptor and potency descriptions and the withdrawal symptom groups, is reviewed by Guiding Road's Executive Director.